AtriCure CTO sells 3,657 shares at $55
AtriCure’s Chief Technical Officer sold 3,657 shares under a pre-arranged Rule 10b5-1 trading plan and continues to hold 147,264 shares directly.
Rhea-AI Filing Summary
AtriCure, Inc. (ATRC) reported that Chief Technical Officer Salvatore Privitera sold 3,657 shares of common stock on September 8, 2026 at a price of $55.00 per share in a sale described as an open market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2026, indicating it was pre-arranged. Following this transaction, Privitera directly holds 147,264 shares of AtriCure common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 3,657 shares
Net Sell
1 txn
Insider
Privitera Salvatore
Role
Chief Technical Officer
Sold
3,657 shs ($201K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 3,657 | $55.00 | $201K |
Holdings After Transaction:
Common Stock — 147,264 shares (Direct)
Footnotes (1)
- F1. These shares were sold pursuant to a 10b5-1 trading plan adopted on February, 20, 2026.
Key Figures
Shares sold: 3,657 shares
Sale price per share: $55.00 per share
Shares held after transaction: 147,264 shares
+3 more
6 metrics
Shares sold
3,657 shares
Common stock sale by Chief Technical Officer on September 8, 2026
Sale price per share
$55.00 per share
Price for the 3,657 shares sold on September 8, 2026
Shares held after transaction
147,264 shares
Direct holdings of Salvatore Privitera following the sale
Net shares sold
3,657 shares
Net change in common stock holdings reported in this Form 4
Transaction date
September 8, 2026
Date of the reported sale of common stock
10b5-1 plan adoption date
February 20, 2026
Adoption date of the trading plan under which the sale occurred
Key Terms
Rule 10b5-1 trading plan, open market or private transaction, Form 4
3 terms
Rule 10b5-1 trading plan regulatory
"These shares were sold pursuant to a 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open market or private transaction financial
"Sale in open market or private transaction"
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did AtriCure (ATRC) disclose in this Form 4?
AtriCure disclosed that Chief Technical Officer Salvatore Privitera sold 3,657 shares of common stock on September 8, 2026 at $55.00 per share in an open market or private transaction under a Rule 10b5-1 trading plan.
Was the AtriCure (ATRC) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the 3,657-share sale on September 8, 2026 was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2026, and the Rule 10b5-1 checkbox is affirmed.
What role does the insider hold at AtriCure (ATRC) in this Form 4?
The reporting person, Salvatore Privitera, is identified as AtriCure’s Chief Technical Officer in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.